-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NFS-02 in Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NFS-02 in Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NFS-02 in Leber's Hereditary Optic Neuropathy...
-
Product Insights
NewOptic Nerve Injury – Drugs In Development, 2024
Empower your strategies with our Optic Nerve Injury – Drugs In Development, 2024 report and make more profitable business decisions. Optic Nerve Injury or optic neuropathy is a common cause of vision loss occurring as a result of damage to the optic nerve. Optic nerve is a group or bundle of nerve fibers that carry out the communication between the eyes and brain. Trauma can be a common cause or complicated cases of diabetic retinopathy can also cause ONI. Neuroimaging studies...
-
Product Insights
NewLeber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Drugs In Development, 2024
Empower your strategies with our Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) – Drugs In Development, 2024 report and make more profitable business decisions. Leber’s hereditary optic neuropathy (LHON) is an inherited form of vision loss. This condition usually begins in a person's teens or twenties; rare cases may appear in early childhood or later in adulthood. Males are affected much more often than females. Symptoms include eye pain or discomfort, numbness, tingling, and clouding of vision. Predisposing factors include age,...
-
Product Insights
NewRetinal Degeneration – Drugs In Development, 2024
Empower your strategies with our Retinal Degeneration – Drugs In Development, 2024 report and make more profitable business decisions. Retinal degeneration refers to a group of diseases that cause progressive damage to the cells of the retina, the light-sensitive tissue at the back of the eye crucial for vision. These conditions lead to a gradual loss of vision, which can range from mild to severe and can eventually result in blindness. There are several types of retinal degenerative diseases, including: Retinitis...
-
Product Insights
NewMacular Edema – Drugs In Development, 2024
Empower your strategies with our Macular Edema – Drugs In Development, 2024 report and make more profitable business decisions. Macular edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appear changed. There are many causes of macular edema. It is frequently associated with diabetes, where damaged blood vessels in the retina begin to leak fluids, including small amounts of blood, into the...
-
Product Insights
NewGlaucoma – Drugs In Development, 2024
Empower your strategies with our Glaucoma – Drugs In Development, 2024 report and make more profitable business decisions. Glaucoma is a disease of the eye in which fluid pressure within the eye rises. The exact cause of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow to the optic nerve. The most important risk factors include age, elevated eye pressure, African ancestry, thin cornea, and family history of glaucoma. Signs and symptoms include...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NFS-02 in Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.NFS-02 in Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) Drug Details: NFS-02 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NFS-01
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry NFS-01 Drug Details NFS-01 is under development for the treatment of Leber hereditary optic...
-
Product Insights
Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Leber’s hereditary optic neuropathy (LHON) symptoms include eye pain or discomfort, numbness, tingling, and clouding of vision. Predisposing factors include age, tobacco smoke, alcohol, cancer-treating drugs, stress-related chemicals, some antibiotics, and cyanogens. The LHON pipeline drugs market research report provides an analysis of the LHON drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history,...